Abiopharma

🔍 ADAR1 Capital Management, LLC (Executive)

Company: TENAX THERAPEUTICS, INC. (TENX)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 403,571 shares of Common Stock at $1.7905 per share (Direct)
  Date: 2026-08-31 | Code: P | equity_swap_involved: 0 | shares_owned_after: 5,257,389.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Acquired 179,058 shares of Common Stock at $1.7959 per share (Direct)
  Date: 2026-09-01 | Code: P | equity_swap_involved: 0 | shares_owned_after: 5,436,447.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Acquired 187,704 shares of Common Stock at $1.7985 per share (Direct)
  Date: 2026-09-02 | Code: P | equity_swap_involved: 0 | shares_owned_after: 5,624,151.00 | transaction_form_type: 4 | Footnotes: F3, F4

Footnotes:

• F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
• F2: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
• F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7750 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
• F4: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
• F5: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.